Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

This study tests the combination of two targeted drugs — APG-1252 (pelcitoclax) and cobimetinib — in women with recurrent ovarian cancer or endometrial cancer that has come back after prior treatment. **You may be eligible if...** - You are 18 or older - You have recurrent ovarian, fallopian tube, peritoneal, or endometrial cancer that has spread or cannot be surgically removed - You have had at least one prior platinum-based chemotherapy treatment - For ovarian cancer: your cancer progressed within 6 months of your last platinum treatment (platinum-resistant) - If you have low-grade serous ovarian cancer: you must have received a prior MEK inhibitor - If you have MSI-high or dMMR endometrial cancer: you must have received or be ineligible for immunotherapy **You may NOT be eligible if...** - You have never received platinum-based chemotherapy - You are pregnant or unwilling to use contraception - Your organ function is significantly impaired - You have serious cardiovascular or other conditions that would make treatment unsafe Talk to your doctor to see if this trial is right for you.